Available Programs

Are you confident selecting between available therapies for hemophilia A? Over the past few decades, the care for patients with hemophilia A has drastically improved, while also becoming more complex, with the advent of new therapeutic options for this challenging disease. This educational activity reviews FDA-approved and investigational products used for this disease and the corresponding data for these agents. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California…

Inhibitors affect approximately 30% of patients with severe hemophilia A. In addition to substantial treatment and medical costs, patients with hemophilia who have inhibitors are twice as likely to be hospitalized for a bleeding complication. This educational activity addresses risk factors for inhibitor development, testing and monitoring strategies, the role of immune tolerance induction, and the use of bypassing agents in the setting of an inhibitor. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical…

How do you encourage medication adherence in your patients with hemophilia A? Several factors influence treatment adherence in hemophilia A, such as understanding treatment benefits, disease severity, venous access, clinic transitions, and insurance coverage. This educational activity discusses adherence barriers, strategies to promote adherence, and the role of the care team to address adherence in this population. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California Pasadena, CA Medical…

The incidence of acute myeloid leukemia (AML) has increased due to an aging population, risk from environmental exposures, and treatment-related/secondary AML in survivors of young and childhood cancers. Members of the hematology/oncology care team are challenged to keep apprised of clinical data, incorporate novel agents into their clinical practice, and manage side effects of newer therapies. In this activity, Dr Daniel Pollyea and Dr Amer Zeidan provide expert commentary on 2 challenging clinical case scenarios focused on management of AML.…

The development of direct oral anticoagulants (DOACs) has advanced the therapeutic landscape for the management of thromboembolic events. Specific agents that rapidly reverse the effects of DOACs are now available and offer safe and effective options for patients who experience an emergency DOAC-associated bleeding event. This interactive activity will offer clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and clinical decision support tools to optimize outcomes in…

Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. While systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD? Join Doris Ponce, MD, and Corey Cutler, MD, MPH, for this podcast as they discuss different novel therapeutic options for managing aGVHD refractory to steroids. This activity is jointly…

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Diabetes represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Diabetes represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Diabete-s represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Did you know the average life span of Americans with sickle cell disease is 20 to 30 years less than those without sickle cell disease? New clinical approaches and treatments can lead to increased survival. In this 30-minute CME activity, Dr Biree Andemariam and Dr Laura De Castro explore current evidence-based approaches, review available agents, and discuss strategies to encourage clinical trial participation among patients. Join us to learn the latest information on this challenging disease. https://www.mycme.com/courses/the-time-is-now-advancing-the-care-of-adolescent-and-adult-patients-with-sickle-cell-disease-7500    

Patients with multiple sclerosis (MS) often need the intervention of multiple specialists, resulting in a complex organization of care. Listen in to this team of healthcare professionals from the MS Comprehensive Care Center at Holy Name Medical Center, who share their insights on best practices for patient-centered care of people with MS. The MS Care Team share key aspects of their evolution as a team using two cases of patients with MS. This discussion highlights how they 1) evaluate existing…

Have you heard about the latest clinical advances in AML therapy? Recent approvals and emerging therapies, such as epigenetic agents and newer cytotoxics, has transformed the care of patients with newly diagnosed and relapsed/refractory AML. Join Dr Stephen A. Strickland and Dr Eunice S. Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management. Click here to listen to this 45-minute CME podcast: https://www.mycme.com/courses/new-therapeutic-options-in-aml-an-update-for-community-clinicians-7573

This online educational podcast offers clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and practical strategies for aligning clinical practice with local hospital bleeding management protocols. Join Dr Colin Kaide and Eric Cucchi as they examine the latest recommendations for the management of life-threatening DOAC-associated bleeding. Click here to enroll and listen to this 37-minute ACEP Frontline Podcast: https://www.acep.org/education/podcasts-and-apps/  

Despite advances in HER targeting, HER2-positive metastatic breast cancer typically progresses. Research has established that the HER2-HER3 complex is the true driver of HER2-amplified cancer and the effective inactivation of this complex is the new bar for novel therapies. In this interactive educational activity, Dr Hurvitz and Dr Tolaney share key data and expert perspectives on recently approved and emerging HER-targeted therapies for metastatic breast cancer. Sara A. Hurvitz, MD, FACP, Professor of Medicine, Director, Breast Oncology Program, Division of…

Four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are approved for migraine prevention. To ensure clinicians are prepared to consider these agents when clinically indicated, this educational activity will compare the efficacy and safety of these therapies for migraine prevention and discuss strategies for shared decision-making. Cynthia E. Armand, MD, Assistant Professor of Neurology Albert Einstein College of Medicine, Fellowship Director Montefiore Headache Center, Bronx, NY Carrie Dougherty, MD, FAHS, Associate Professor of Neurology Program Director, Headache Medicine Fellowship, Assistant Program Director, Neurology…

My migraines made me feel like I was a part-time parent. They were so bad that my husband and I came to the difficult decision that we could not have more kids because I could not function as a parent ‒ I could barely function as an adult.” Do you know how migraine affects the daily lives of your patients? Join Dr Cynthia Armand and Dr Carrie Dougherty to learn more about caring for patients with this debilitating disease. Cynthia…